Marian W. Wentworth is President and Chief Executive Officer of MSH. A leader in managing complex international public health initiatives across diverse cultures, she uses her private sector and nonprofit acumen to address global health challenges from new vantage points. Since 2017, Wentworth has helped MSH make highly effective, sustainable systemic improvements in some of the globe’s most challenging environments. 

Before coming to MSH, Wentworth managed global strategy for marketing, manufacturing, and research at Merck & Co for more than 25 years, including the company’s $6 billion dollar vaccines business. A champion for adolescent health, she led the global sales and marketing launch of the world’s first cervical cancer vaccine, Gardasil. She also managed adult vaccines for shingles, influenza, pneumococcal disease, hepatitis B, hepatitis A, and tetanus. Earlier in her career, Wentworth was a consultant in operations management at Arthur D. Little, Inc.

Sharing her substantial experience in the vaccine market, Wentworth served for six years (from 2018 through 2024) on the WHO’s Product Development for Vaccines Advisory Committee (PDVAC). Wentworth is a Member of the Dean’s Advisory Council at Drexel University’s School of Public Health and Chair of the board of a Kenyan supply chain company, MedSource.

Wentworth has a B.A. in mathematics from Harvard University.